Imatinib mesylate and nilotinib (AMN107) exhibit high-affinity interaction with ABCG2 on primitive hematopoietic stem cells. (Q33285468)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17519960%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

title

Imatinib mesylate and nilotinib (AMN107) exhibit high-affinity interaction with ABCG2 on primitive hematopoietic stem cells (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17519960%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

1 reference

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17519960%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

Gunther Wennemuth

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17519960%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

5

S E Bates

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17519960%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

author name string

C Brendel

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17519960%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

C Scharenberg

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17519960%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

M Dohse

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17519960%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

S Shukla

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17519960%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

S V Ambudkar

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17519960%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

Y Wang

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17519960%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

A Burchert

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17519960%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

U Boudriot

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17519960%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

A Neubauer

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17519960%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

publication date

22 March 2007

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17519960%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17519960%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

volume

21

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17519960%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17519960%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

page(s)

1267-1275

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17519960%20AND%20SRC:MED&resulttype=core&format=json

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells

31 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404638

Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404638

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404638

Dynamics of chronic myeloid leukaemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404638

Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404638

Discontinuation of imatinib therapy after achieving a molecular response

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404638

Clinical resistance to the kinase inhibitor STI-571 in chronic myeloid leukemia by mutation of Tyr-253 in the Abl kinase domain P-loop

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404638

Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404638

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404638

Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404638

Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404638

Functional ABCG2 is overexpressed on primary CML CD34+ cells and is inhibited by imatinib mesylate

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404638

Active transport of imatinib into and out of cells: implications for drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404638

Imatinib mesylate is a potent inhibitor of the ABCG2 (BCRP) transporter and reverses resistance to topotecan and SN-38 in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404638

Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404638

High-affinity interaction of tyrosine kinase inhibitors with the ABCG2 multidrug transporter

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404638

AMN107, a novel aminopyrimidine inhibitor of p190 Bcr-Abl activation and of in vitro proliferation of Philadelphia-positive acute lymphoblastic leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404638

Advances in the structural biology, design and clinical development of Bcr-Abl kinase inhibitors for the treatment of chronic myeloid leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404638

AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has in vitro activity against imatinib-resistant chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404638

In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404638

Chronic myelocytic leukemia: Clonal origin in a stem cell common to the granulocyte, erythrocyte, platelet and monocyte/macrophage

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404638

The ABCG2 transporter is an efficient Hoechst 33342 efflux pump and is preferentially expressed by immature human hematopoietic progenitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404638

The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404638

Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404638

Bcrp1 gene expression is required for normal numbers of side population stem cells in mice, and confers relative protection to mitoxantrone in hematopoietic cells in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404638

Pharmacokinetic resistance to imatinib mesylate: role of the ABC drug pumps ABCG2 (BCRP) and ABCB1 (MDR1) in the oral bioavailability of imatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404638

Akt signaling regulates side population cell phenotype via Bcrp1 translocation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404638

The calcium channel blockers, 1,4-dihydropyridines, are substrates of the multidrug resistance-linked ABC drug transporter, ABCG2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404638

The long-term repopulating subset of hematopoietic stem cells is deterministic and isolatable by phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404638

Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe Against Cancer program.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404638

Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404638

Gene expression profiles of AML derived stem cells; similarity to hematopoietic stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404638

Clinical pharmacokinetics of imatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404638

Plasma and cerebrospinal fluid pharmacokinetics of imatinib after administration to nonhuman primates

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404638

Myelodysplastic syndromes and acute leukemia developing after imatinib mesylate therapy for chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404638

Adaptive secretion of granulocyte-macrophage colony-stimulating factor (GM-CSF) mediates imatinib and nilotinib resistance in BCR/ABL+ progenitors via JAK-2/STAT-5 pathway activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404638

Complex interaction of BCRP/ABCG2 and imatinib in BCR-ABL-expressing cells: BCRP-mediated resistance to imatinib is attenuated by imatinib-induced reduction of BCRP expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404638

Circumventing Resistance to Kinase-Inhibitor Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404638

OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404638

Survival benefit with imatinib mesylate versus interferon-alpha-based regimens in newly diagnosed chronic-phase chronic myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404638

7 January 2021

Primitive quiescent leukemic cells from patients with chronic myeloid leukemia spontaneously initiate factor-independent growth in vitro in association with up-regulation of expression of interleukin-3

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404638

7 January 2021

Unexpectedly efficient homing capacity of purified murine hematopoietic stem cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404638

7 January 2021

Central nervous system failure in patients with chronic myelogenous leukemia lymphoid blast crisis and Philadelphia chromosome positive acute lymphoblastic leukemia treated with imatinib (STI-571).

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404638

7 January 2021

The effect of Bcrp1 (Abcg2) on the in vivo pharmacokinetics and brain penetration of imatinib mesylate (Gleevec): implications for the use of breast cancer resistance protein and P-glycoprotein inhibitors to enable the brain penetration of imatinib

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404638

7 January 2021

Identifiers

DOI

10.1038/SJ.LEU.2404638

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17519960%20AND%20SRC:MED&resulttype=core&format=json

Dimensions Publication ID

31 December 2019

1025136515

0 references

1 reference